All News Oneness Biotech Co., Ltd.

Equities

4743

TW0004743000

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
159 ^TWD	+3.92%		+6.71%	-18.25%

Mar. 29	Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol to Taiwan FDA for Subcutaneous Injection Formulation ofFB825 in Patients with Moderate-To-Severe Atopic Dermatitis	CI
Mar. 11	Oneness Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol to Taiwan FDA for Subcutaneous Injection Formulation ofFB825 in Patients with Moderate-To-Severe Atopic Dermatitis	Mar. 29	CI
Oneness Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol Forsubcutaneous Injection Formulation of FB825 in Patientswith Moderate-To-Severe Atopic Dermatitis	Jan. 30	CI
Oneness Biotech Co., Ltd. Obtains Import License in Thailand from Thai Food and Drug Administration	Jan. 18	CI
Oneness Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Oneness Biotech Co., Ltd. Announces Approval of FESPIXON	Nov. 09	CI
Oneness Submits Medical Device Registration Application of Bonvadis for Wound Care to the Thai Food and Drug Administration in Thailand	23-10-25	CI
Oneness Biotech Co., Ltd. Submits 510(k) Application to the U.S. FDA to Expand the Intended Patient Population and Add Multiple Chronic Wound Indications for Bonvadis	23-08-31	CI
Oneness Biotech Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Oneness Biotech Co., Ltd. Obtains Import License for Bonvadis, The Wound Care Topical Cream in South Africa	23-08-09	CI
Oneness Biotech Co., Ltd. Announces Submission of Registration Application for Bonvadis, the Wound Care Topical Cream to the Drug Regulatory Authority of Pakistan	23-08-04	CI
US FDA agrees to proceed with Phase 2 clinical trial for SNS812, a broad-spectrum siRNA for COVID-19 infection, co-developed by Oneness & Microbio	23-08-02	CI
Oneness Biotech Co., Ltd. Receives Approval from Malaysia NPRA for FESPIXON, the New Drug in Treatment of Diabetic Footulcers	23-07-14	CI
Oneness Biotech Co., Ltd. Announces the National Agency of Drug and Food Control Accepts the NDA Application of the Diabetic Foot Ulcer New Drug, Fespixon	23-06-06	CI
Oneness Biotech Co., Ltd. Submits IND to US FDA for a Phase II Clinical Trial on the Broad-Spectrum Anti-SARS-CoV-2siRNA Co-Developed with Microbio	23-05-31	CI
Oneness Biotech Co., Ltd. Announces Cash Dividend, Payable on July 21, 2023	23-05-30	CI
Oneness Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Oneness and Microbio Co., Ltd. Announces the Phase 1 Clinical Trial Data of Sns812	23-04-28	CI
Oneness Announces Bonvadis Cream for Scar Management Has Been Granted Import License in Europe	23-04-27	CI
Oneness Receives Medical Devices Export License Approvals by TFDA on Bonvadis Topical Cream and Bonvadis Cream	23-03-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Oneness Biotech Co., Ltd.

Equities

4743

TW0004743000

All News

Filters